ASPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -192.33 Med: -7.2 Max: 45.04
Current: 45.04
During the past 10 years, the highest EV-to-FCF of Ascentage Pharma Group International was 45.04. The lowest was -192.33. And the median was -7.20.
ASPHF's EV-to-FCF is ranked worse than 74.55% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs ASPHF: 45.04
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascentage Pharma Group International (OTCPK:ASPHF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascentage Pharma Group International's PE Ratio (TTM) for today is calculated as:
Ascentage Pharma Group International's share price for today is $4.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.491.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ascentage Pharma Group International EV-to-FCF Related Terms
Ascentage Pharma Group International EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International EV-to-FCF Chart
For the Biotechnology subindustry, Ascentage Pharma Group International's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International EV-to-FCF vs Biotechnology Industry
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $32.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a EV-to-FCF of 44.66 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ascentage Pharma Group International and its competitors. According to the industry distribution chart, Ascentage Pharma Group International ranks #246 out of 330 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Ascentage Pharma Group International's EV-to-FCF too high?
Ascentage Pharma Group International's current EV-to-FCF is 44.66. The Biotechnology industry median EV-to-FCF is 14.97. Ascentage Pharma Group International's value of 44.66 is 198.3% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #246 out of 330 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #246 out of 330 companies for EV-to-FCF. This places Ascentage Pharma Group International in the lower half of its industry. The industry median EV-to-FCF is 14.97. Ascentage Pharma Group International's value of 44.66 is 198.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current EV-to-FCF of 44.66 is 198.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current EV-to-FCF is 44.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current EV-to-FCF is 44.66 and 198.3% above the Biotechnology industry median of 14.97. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current EV-to-FCF is 44.66 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
EV-to-FCF: 44.66
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
Industry Position: 198.3% above the Biotechnology median (#246 of 330)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
